UK markets open in 4 hours 45 minutes

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.2999+0.0499 (+1.54%)
At close: 10:58AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.2500
Open3.2200
Bid1.8000 x 1300
Ask4.0600 x 1000
Day's range3.2500 - 3.2999
52-week range3.0400 - 6.6500
Volume599
Avg. volume18,122
Market cap260.798M
Beta (5Y monthly)0.12
PE ratio (TTM)N/A
EPS (TTM)-0.9540
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.19
  • Globe Newswire

    NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF JULY 1, 2021

    Marseille, France, July 12, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as of July 1, 2021: Total number of shares outstanding:79,031,980 ordinary shares 6,796 Pre

  • Globe Newswire

    Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

    Investigator-sponsored FORCE trial did not meet primary endpoints Company will stop exploring avdoralimab in COVID-19 Investigator-sponsored avdoralimab clinical trial in inflammation will continue MARSEILLE, France, July 06, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that FORCE (FOR COVID-19 Elimination), the investigator-sponsored, Phase 2 clinical trial evaluating the safety and efficacy of its

  • Globe Newswire

    Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy

    Marseille, France, June 16, 2021 (GLOBE NEWSWIRE) -- Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKETTM Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual investor event on Wednesday, June 23, 2021, at 2 p.m. CEST / 8 a.m. EDT. The event will feature presentations and an interactive Q&A session from the Company's executive le